SELLAS Life Sciences Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

SELLAS Life Sciences Group şirketinin toplam hissedar öz sermayesi $2.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $15.1M ve $12.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$9.15m
Eşitlik	US$2.91m
Toplam yükümlülükler	US$12.21m
Toplam varlıklar	US$15.12m

Son finansal sağlık güncellemeleri

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Mar 08

Recent updates

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jun 18

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jul 13

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Sep 20

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

Aug 09

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Mar 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Nov 23

Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

Jul 19

SELLAS Life Sciences updates on at-the-market offering

Jun 02

SELLAS Life Sciences jumps 43% after Reddit mentions

Feb 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SLS 'nin kısa vadeli varlıkları ( $12.3M ) kısa vadeli yükümlülüklerini ( $12.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: SLS şirketinin kısa vadeli varlıkları ( $12.3M ) uzun vadeli yükümlülüklerini ( $161.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SLS borçsuzdur.

Borcun Azaltılması: SLS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SLS son raporlanan serbest nakit akışına göre 3 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: SLS serbest nakit akışı tahminlerine göre 3 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

SELLAS Life Sciences Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Recent updates

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Price target decreased by 17% to US$5.83

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

Consensus EPS estimates fall by 19%

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

New minor risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

Consensus EPS estimates upgraded to US$0.87 loss

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

New major risk - Financial position

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 18%

Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

Consensus revenue estimates increase by 200%

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)

Price target decreased by 25% to US$6.00

SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer

SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality

SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies

SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study

Insufficient new directors

SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer

SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Insufficient new directors

SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009

SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021)

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

Price target decreased to US$13.75

Insufficient new directors

SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S